|
- Pembrolizumab or placebo with chemoradiotherapy followed by . . .
Summary Background Pembrolizumab has shown efficacy in persistent, recurrent, or metastatic cervical cancer The effect of chemoradiotherapy might be enhanced by immunotherapy In this phase 3 trial, we assessed the efficacy and safety of adding pembrolizumab to chemoradiotherapy in locally advanced cervical cancer
- Pembrolizumab With Chemoradiotherapy for FIGO 2014 Stage . . . - ASCO Post
On January 12, 2024, pembrolizumab (Keytruda) was approved for use with chemoradiotherapy for treatment of patients with International Federation of Gynecology and Obstetrics (FIGO) 2014 stage III–IVA cervical cancer 1 Supporting Efficacy Data Approval was based on findings in the double-blind KEYNOTE-A18 study (ClinicalTrials gov identifier NCT04221945) A total of 1,060 patients with no
- Pembrolizumab CCRT Yields Significant Efficacy in Advanced Cervical Cancer
A statistically significant and or clinically meaningful improvement in efficacy was noted when pembrolizumab (Keytruda) plus chemoradiotherapy followed by pembrolizumab was used to treat patients with newly diagnosed, previously untreated, high-risk, stage IB to IIB with node-positive disease or stage III to IVA disease regardless of nodal status in locally advanced cervical cancer, according
- Real-world outcomes after pembrolizumab treatment for cervical cancer . . .
This retrospective study included patients treated with pembrolizumab for advanced or recurrent cervical cancer at a tertiary academic center Data were collected from patients initiating pembrolizumab treatment after May 2018 through June 2023 Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method
- Pembrolizumab Plus Concurrent Chemoradiation Represents New SOC for . . .
What did data from the second interim analysis demonstrate about the efficacy of pembrolizumab combined with concurrent chemoradiotherapy in patients with high-risk, locally advanced cervical cancer?
- Combination Results in Patients With Advanced Cervical Cancer - KEYTRUDA
See how KEYTRUDA® (pembrolizumab) may be used with other chemotherapy medicines for people with certain types of advanced cervical cancer Explore clinical trial results
- Keytruda Plus Chemo Improves Progression-Free Survival in Cervical Cancer
The addition of Keytruda to external beam radiotherapy and concurrent chemotherapy, followed by brachytherapy, resulted in statistically significant and clinically meaningful improvements in progression-free survival in patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer
- Efficacy Data for KEYTRUDA® (pembrolizumab) | KEYNOTE Trials
Select a Cancer Type Browse the indications approved for treatment with KEYTRUDA® (pembrolizumab) Open to review efficacy and safety information, and you will also find links to related information like dosing, mechanism of action, and more If you're using the filter, you'll only see the indications you have selected
|
|
|